CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a major pharmaceutical enterprise based in China engaged in the research, development, manufacture, and sale of pharmaceutical products. The company offers finished drugs across oncology, central nervous system, cardiovascular, anti-infective, and metabolic therapeutic areas, alongside bulk active pharmaceutical ingredients such as vitamin C and antibiotics. Principal revenue drivers consist of prescription formulation sales, oncology therapeutics, and bulk pharmaceutical raw materials distributed globally. CSPC serves public and private hospitals, retail pharmacies, healthcare institutions, and international industrial buyers across mainland China and export markets. The company holds a prominent position within the Chinese pharmaceutical sector as a leading developer of generic and innovative medicines. CSPC Pharmaceutical Group Limited is headquartered in Shijiazhuang, China, and its common shares are listed on the Stock Exchange of Hong Kong.
29 of the funds FundTelligence covers report a position in CSPC Pharmaceutical Group.
- Legal name
- CSPC Pharmaceutical Group Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 29
Funds holding CSPC Pharmaceutical Group
- UBS All China Equity Fund — UBS · 3.0 % (largest positions only, September 2026)
- Schroder ISF China Opportunities — Schroders · 1.39 % (full portfolio disclosed, June 2026)
- Schroder ISF All China Equity — Schroders · 1.17 % (full portfolio disclosed, June 2026)
- BNP China Equity — BNP Paribas · 1.07 % (full portfolio disclosed, June 2026)
- Schroder ISF Greater China — Schroders · 0.92 % (full portfolio disclosed, June 2026)
- Schroder ISF Emerging Asia — Schroders · 0.61 % (full portfolio disclosed, June 2026)
- Handelsbanken Vekstmarked Tema — Handelsbanken · 0.54 % (full portfolio disclosed, September 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.5 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 29 funds holding it.